Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137321 | 0.85 | KDM4E (0.36) | LMNASMN1; SMN2MAPK1CA2ALDH1A1 | |
| SCHEMBL8777225 | 0.85 | LMNA (0.40) | ATMLMNASMN1; SMN2HTTGAA | |
| SCHEMBL9829512 | 0.84 | ATM (0.38) | ATMLMNASMN1; SMN2HTTGAA | |
| SCHEMBL9829508 | 0.84 | ATM (0.38) | ATMLMNASMN1; SMN2HTTGAA | |
| SCHEMBL7765983 | 0.83 | LMNA (0.39) | ATMLMNASMN1; SMN2HTTGAA | |
| SCHEMBL7765993 | 0.83 | ALOX15 (0.40) | ATMLMNASMN1; SMN2HTTGAA | |
| SCHEMBL12412303 | 0.83 | MGAM (0.40) | ATMLMNASMN1; SMN2HTTGAA | |
| SCHEMBL1534984 | 0.82 | EPHX1 (0.43) | ATMSMN1; SMN2MAPK1ALDH1A1RAB9A | |
| SCHEMBL697937 | 0.82 | EPHX1 (0.43) | ATMSMN1; SMN2MAPK1ALDH1A1RAB9A | |
| SCHEMBL8234485 | 0.81 | MMP3 (0.47) | MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087085-B1 | SYNTHESIS OF A MACROCYCLIC HCV NS3 INHIBITING TRIPEPTIDE | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8067438-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-21 | — | — | US | disclosed |
| US-7939667-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-7939667-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-7585845-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-08 | — | — | US | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210756-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, MAVS, SARS1 | ATM 2874/4885LMNA 3646/4885SMN1; SMN2 2417/4885 |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | ATM 4362/4885LMNA 816/4885SMN1; SMN2 4624/4885 |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | ATM 4362/4885LMNA 816/4885SMN1; SMN2 4624/4885 |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | ATM 4362/4885LMNA 816/4885SMN1; SMN2 4624/4885 |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | ATM 4362/4885LMNA 816/4885SMN1; SMN2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.